Seikagaku takes forward Can-Fite's arthritis therapy
This article was originally published in Scrip
Executive Summary
Seikagaku has begun the clinical development in Japan of Can-Fite BioPharma's lead compound, SI-615 (CF101), for the treatment of rheumatoid arthritis (RA).